Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane (Matrigel).
We have investigated the adhesive properties and invasiveness of cells of the human ovarian carcinoma line, NIH:OVCAR-3, in vitro. OVCAR-3 cells exhibited a similar rate of adhesion to all substrates tested including laminin, fibronectin, and collagens I and IV. The synthetic peptide YIGSR-NH2, which corresponds to an attachment site in laminin, inhibited the adhesion of the cells to laminin, but not to fibronectin. In contrast, a GRGDS-NH2 peptide blocked adhesion to fibronectin but not to laminin. OVCAR-3 cells invaded and formed branched colonies on Matrigel. Colony formation was retarded by both YIGSR-NH2 and GRGDS-NH2 peptides. Serine protease inhibitors and human recombinant TIMP, the tissue inhibitor of metalloproteases, inhibited ovarian tumor cell invasion while a synthetic collagenase IV inhibitor (SC-44463) had no effect. These studies suggest that metalloproteases other than collagenase IV may be important for the invasive activity of ovarian cancer cells. It is possible that synthetic peptides with antiadhesive cellular activity and certain antiproteases could be used to control the progressive colonization and invasion of peritoneal surfaces by malignant ovarian cancer cells.
Laboratory of Developmental Biology and Anomalies, National Institute of Dental Research, NIH, Bethesda, Md.
T
T
Kanemoto
G R
GR
Martin
T C
TC
Hamilton
R
R
Fridman
D000577:Amides; D000595:Amino Acid Sequence; D000614:Aminocaproates / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001550:Benzamidines / Q000494:pharmacology; D001672:Biocompatible Materials; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D002633:Chemotaxis / Q000187:drug effects; D003094:Collagen; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D006023:Glycoproteins / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007797:Laminin / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness; D009842:Oligopeptides / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D010436:Pepstatins / Q000494:pharmacology; D011073:Polyamines / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology*; D011509:Proteoglycans; D019714:Tissue Inhibitor of Metalloproteinases; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000031:analogs & derivatives*
D000577:Amides; D000614:Aminocaproates; D000970:Antineoplastic Agents; D001550:Benzamidines; D001672:Biocompatible Materials; D004338:Drug Combinations; D006023:Glycoproteins; D007797:Laminin; D007976:Leupeptins; D009842:Oligopeptides; D010436:Pepstatins; D011073:Polyamines; D011480:Protease Inhibitors; D011509:Proteoglycans; D019714:Tissue Inhibitor of Metalloproteinases; C081572:tyrosyl-isoleucyl-glycyl-seryl-argininamide; C065557:N-(2-isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; C014195:Streptomyces pepsin inhibitor; C059485:matrigel; D014443:Tyrosine; D003094:Collagen; C049554:glycyl-arginyl-glycyl-aspartyl-serine; C058347:glycyl-arginyl-glycyl-glutamyl-seryl-proline; D008666:Metalloendopeptidases; C032854:leupeptin; C032157:benzamidine; C031375:pepstatin